Pharmacokinetics and pharmacodynamics of levodopa
- PMID: 18781675
- DOI: 10.1002/mds.22037
Pharmacokinetics and pharmacodynamics of levodopa
Abstract
The pharmacokinetics and pharmacodynamics of levodopa are dominated by two features: the short plasma half-life of the drug and the portion of the antiparkinsonian response that parallels the plasma levodopa levels, the so-called short-duration response. These features are the basis of motor fluctuations that complicate long-term therapy with levodopa. Motor fluctuations will predictably improve with measures that prolong the elevations of plasma levodopa or prolong the efficacy of dopamine synthesized from exogenous levodopa. Because dyskinesia is closely linked to the short-duration response and conceivably part of the short-duration response, it is less clear that dyskinesia will be improved by therapeutic strategies that reduce motor fluctuations.
(c) 2008 Movement Disorder Society.
Similar articles
-
Role of integrative pharmacokinetic and pharmacodynamic optimization strategy in the management of Parkinson"s disease patients experiencing motor fluctuations with levodopa.J Pharm Pharm Sci. 2002 May-Aug;5(2):146-61. J Pharm Pharm Sci. 2002. PMID: 12207867
-
Evolution of the response to levodopa during the first 4 years of therapy.Ann Neurol. 2002 Jun;51(6):686-93. doi: 10.1002/ana.10189. Ann Neurol. 2002. PMID: 12112073
-
Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease.Mov Disord. 1997 May;12(3):285-92. doi: 10.1002/mds.870120304. Mov Disord. 1997. PMID: 9159720
-
Treatment of levodopa-induced motor complications.Mov Disord. 2008;23 Suppl 3:S599-612. doi: 10.1002/mds.22052. Mov Disord. 2008. PMID: 18781681 Review.
-
Motor fluctuations in levodopa treatment: clinical pharmacology.Eur Neurol. 1996;36 Suppl 1:38-42. doi: 10.1159/000118882. Eur Neurol. 1996. PMID: 8791020 Review.
Cited by
-
Closing the loop for patients with Parkinson disease: where are we?Nat Rev Neurol. 2022 Aug;18(8):497-507. doi: 10.1038/s41582-022-00674-1. Epub 2022 Jun 9. Nat Rev Neurol. 2022. PMID: 35681103 Review.
-
Efficacy and safety of levodopa-carbidopa intestinal gel from a study in Japanese, Taiwanese, and Korean advanced Parkinson's disease patients.NPJ Parkinsons Dis. 2016 Nov 3;2:16020. doi: 10.1038/npjparkd.2016.20. eCollection 2016. NPJ Parkinsons Dis. 2016. PMID: 28725701 Free PMC article.
-
The role of neuroplasticity in dopaminergic therapy for Parkinson disease.Nat Rev Neurol. 2013 May;9(5):248-56. doi: 10.1038/nrneurol.2013.57. Epub 2013 Apr 16. Nat Rev Neurol. 2013. PMID: 23588357 Review.
-
Optimizing Differentiation Protocols for Producing Dopaminergic Neurons from Human Induced Pluripotent Stem Cells for Tissue Engineering Applications: Supplementary Issue: Stem Cell Biology.Biomark Insights. 2015 May 26;10 Suppl 1:61-70. doi: 10.4137/BMI.S20064. eCollection 2015. Biomark Insights. 2015. PMID: 36876191 Free PMC article.
-
Gender Differences in Levodopa Pharmacokinetics in Levodopa-Naïve Patients With Parkinson's Disease.Front Med (Lausanne). 2022 May 31;9:909936. doi: 10.3389/fmed.2022.909936. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35712091 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
